1. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8(2):79-88.
2. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.
3. Graham DY, El-Serag HB. European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut. 2021;70(1):1-2.
4. Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Internal medicine (Tokyo, Japan). 2010;49(12):1103-9.
5. Lopez-Gongora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. The Journal of antimicrobial chemotherapy. 2015;70(9):2447-55.
6. Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;14(7):383-4.
7. Valdivieso-Garcia A, Imgrund R, Deckert A, et al. Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli. Diagnostic microbiology and infectious disease. 2009;65(2):168-74.
8. von Recklinghausen G, Ansorg R. Metronidazole susceptibility testing of Helicobacter pylori with the PDM epsilometer test (E test). Zentralbl Bakteriol. 1995;282(1):83-5.
9. Alarcon T, Domingo D, Lopez-Brea M. Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. Journal of clinical microbiology. 1998;36(4):1165-6.
10. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001;161(9):1217-20.
11. Neri M, Milano A, Laterza F, et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Alimentary pharmacology & therapeutics. 2003;18(8):821-7.
12. Zhou L, Zhang J, Song Z, et al. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter. 2016;21(2):91-9.
13. Perna, F. Susceptibility of Helicobacter pylori to metronidazole. The American journal of gastroenterology. 2003;98(10):2157-61.
14. Wang WH, Wong BC, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Alimentary pharmacology & therapeutics. 2000;14(7):901-10.
15. Cheng A, Sheng WH, Liou JM, et al. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan. J Microbiol Immunol Infect. 2015;48(1):72-9.
16. Miftahussurur M, Fauzia KA, Nusi IA, et al. E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study. BMC research notes. 2020;13(1).
17. Chaves S, Gadanho M, Tenreiro R, et al. Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. Journal of clinical microbiology. 1999;37(5):1628-31.
18. Osato MS, Reddy R, Reddy SG, et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. International journal of antimicrobial agents. 2001;17(1):39-44.
19. Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]. 2014;45(4):1439-48.
20. Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Alimentary pharmacology & therapeutics. 2019;49(11):1385-94.
21. Luo L, Huang Y, Liang X, et al. Susceptibility‐guided therapy for
Helicobacter pylori
‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies. Helicobacter. 2020;25(4).
22. Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. The Journal of antimicrobial chemotherapy. 1993;31(1):65-71.
23. Glupczynski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2002;21(7):549-52.
24. Citron DM, Ostovari MI, Karlsson A, et al. Evaluation of the E test for susceptibility testing of anaerobic bacteria. Journal of clinical microbiology. 1991;29(10):2197-203.
25. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. The Journal of antimicrobial chemotherapy. 1992;29(2):115-20.
26. Chida-Sakata N, Baba M, Inagawa H, et al. Significance of anaerobic preincubation of Helicobacter pylori for measuring metronidazole susceptibility by the Etest. Microbiol Immunol. 1999;43(5):397-401.
27. Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000;14(6):745-50.
28. Osato MS, Graham DY. Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol. 2004;99(4):769.